← Eichor
Study identifier: NCT06598046 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of Active Brain Metastasis of TNBC

Condition: Metastatic Breast Cancer  ·  Sponsor: Henan Cancer Hospital

PhasePhase 2
Planned participants48
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study aims to explore the efficacy and safety of the combination therapy of utidelone and capecitabine in the treatment of brain metastases from triple-negative advanced breast cancer, and to search for systemic treatment for brain metastases from triple-negative advanced breast cancer cases.

This description comes directly from the study's public registry record.

Talk to the study team

Min Yan, Doctor  ·  +8615713857388  ·  ym200678@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou UniversityZhengzhou, Henan, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06598046